Danaher (DHR) PT Raised to $260 at TD Cowen

TD Cowen analyst Dan Brennan raised the price target on Danaher (NYSE: DHR) to $260.00 (from $250.00) while maintaining a Buy rating.

The analyst commented: "3% '26 Organic Starting Point Sets a Low Bar; EPS Cushion is Evident; Accelerated cost cuts into what could be an easier recovery in '26 offered a clearing event for believers in DHR's bioprocess-driven story despite a mixed print/guide. A first look at '26 highlighted a path to HSD%+ EPS growth despite organic growth at 3%+. While a Bioprocess upturn is evident, weak spots exist (Life Sci, China Dx). Good news: they're assumed in the guide, creating an upside path."

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• Intuitive Machines wins $600M+ satellite communications contract
• Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald on Thalassemia Opportunity